Adequately powered prospective, randomized clinical studies to assess the utility of aldosterone receptor antagonists in patients with CHF and impaired diastolic relaxation such as the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial are ongoing. At this time, however, there are insufficient clinical data to recommend the use of aldosterone antagonist therapy for the treatment of diastolic dysfunction.